Cancer Genetics Company Review & Valuation

Cancer Genetics, Inc.

develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia.

Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation.

Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease.

It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials.

The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics.

Cancer Genetics, Inc.

was founded in 1999 and is based in Rutherford, New Jersey.